The combination of EHBP1L1 inhibition and ICB, which reprograms the immunosuppressive TME and prevents immune evasion, represents a potential therapeutic strategy for improving the efficacy of cancer immunotherapy in RCC patients. This evidence concerns the gene EHBP1L1 and renal cell carcinoma.